AB0416 Early Good Eular Response Predicts Low/Remission Disease State in Rheumatoid Arthritis Patients on Treatment with Certolizumab in Real Life Settings. Data from Italian Registry Gisea
AB0416 Early Good Eular Response Predicts Low/Remission Disease State in Rheumatoid Arthritis Patients on Treatment with Certolizumab in Real Life Settings. Data from Italian Registry Gisea